Inquiry Basket
Loading ......
Lanreotide is a synthetic octapeptide somatostatin analog that selectively binds to somatostatin receptor subtype 2 (SSTR2) and subtype 5 (SSTR5) with high affinity, exerting potent inhibitory effects on the secretion of growth hormone (GH), insulin-like growth factor 1 (IGF-1), and various gastroenteropancreatic hormones. Originally developed as a long-acting therapeutic agent for acromegaly, lanreotide has expanded its clinical reach to encompass the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), where its antisecretory and antiproliferative properties contribute to symptom control and tumor stabilization. As a somatostatin analog formulated in a sustained-release depot injection, lanreotide provides prolonged pharmacological activity through a monthly or extended dosing interval, offering a convenient treatment paradigm compared to conventional daily somatostatin infusions. While lanreotide has demonstrated substantial clinical benefit across multiple indications, the emergence of anti-lanreotide antibody responses in a subset of treated patients raises important immunogenicity concerns that warrant systematic monitoring. The validated Anti-Lanreotide ELISA Kit provides a standardized, quantitative analytical platform for the detection of anti-lanreotide antibodies in human serum and plasma, supporting immunogenicity assessment, pharmacokinetic correlation, and clinical research in the context of somatostatin analog therapy.
Figure 1.Lanreotide ELISA Kit for Quantitative Somatostatin Analog.
Acromegaly is a chronic systemic disorder caused by excessive growth hormone secretion from a pituitary adenoma, leading to progressive acral enlargement, soft tissue swelling, joint degeneration, and metabolic disturbances including insulin resistance and cardiovascular complications. The pathophysiological cascade of acromegaly is mediated primarily through IGF-1, the downstream effector of GH action, which drives tissue overgrowth and organ dysfunction. Somatostatin analog therapy represents the cornerstone of medical management for acromegaly patients who cannot achieve biochemical control through surgery alone, with lanreotide and octreotide serving as the two primary therapeutic options in this class. In the parallel domain of gastroenteropancreatic neuroendocrine tumors, lanreotide addresses the functional hormonal excess that characterizes secreting NET subtypes, alleviating symptoms of carcinoid syndrome, Zollinger-Ellison syndrome, and other hormone-mediated clinical manifestations. Additionally, the antiproliferative action of lanreotide via SSTR-mediated signaling pathways contributes to tumor growth control, as evidenced by the CLARINET trial demonstrating stable disease in non-functioning NET patients receiving lanreotide depot. The clinical efficacy of lanreotide is closely linked to sustained therapeutic drug exposure, and any disruption of drug bioavailability due to immunogenicity-related clearance acceleration can compromise treatment outcomes, underscoring the necessity for reliable anti-drug antibody detection in clinical research and post-marketing surveillance.
Somatostatin receptors (SSTRs) constitute a family of five G-protein-coupled receptor subtypes (SSTR1 through SSTR5) that mediate the diverse physiological actions of endogenous somatostatin and its synthetic analogs. Among these subtypes, SSTR2 and SSTR5 are the primary targets of lanreotide, accounting for its potent suppression of GH secretion from pituitary somatotroph cells and its inhibitory effects on hormonal release from pancreatic endocrine cells and enterochromaffin cells. Upon binding to these receptors, lanreotide activates intracellular signaling cascades that inhibit adenylate cyclase, reduce cyclic AMP levels, suppress calcium influx, and activate protein tyrosine phosphatases, collectively leading to decreased hormone synthesis and secretion. The tissue distribution of SSTR2 and SSTR5 across pituitary adenomas, pancreatic neuroendocrine tumors, and intestinal carcinoid tumors provides the molecular basis for lanreotide's therapeutic efficacy across these disease categories. Understanding the dynamics of SSTR engagement by lanreotide is essential for interpreting pharmacokinetic-pharmacodynamic relationships, as receptor density and occupancy can influence drug clearance through target-mediated drug disposition mechanisms.
The growth hormone-insulin-like growth factor 1 axis represents the primary pathophysiological target of lanreotide in acromegaly treatment. Growth hormone, secreted by anterior pituitary somatotroph cells, stimulates hepatic and peripheral tissue production of IGF-1, which serves as the principal mediator of GH-driven tissue growth and metabolic dysfunction in acromegaly. The biochemical control of acromegaly is defined by normalization of both GH and IGF-1 levels, making these biomarkers essential endpoints for evaluating therapeutic efficacy. Lanreotide reduces GH secretion through SSTR2-mediated inhibition of somatotroph cell activity, with a consequent decline in circulating IGF-1 concentrations that reflects the downstream suppression of the GH-IGF-1 axis. The quantitative relationship between lanreotide drug exposure, GH suppression, and IGF-1 normalization provides critical pharmacodynamic insights that inform dose selection, treatment switching decisions, and individualized therapy optimization. Furthermore, the GH-IGF-1 axis remains relevant in the context of lanreotide-treated neuroendocrine tumors, where GH and IGF-1 modulation may contribute to antiproliferative effects and metabolic homeostasis.
The Anti-Lanreotide ELISA Kit is a quantitative sandwich ELISA designed for the detection and measurement of anti-lanreotide antibodies in human serum and plasma samples, including both EDTA and heparin anticoagulated plasma. This assay employs a lanreotide-coated microplate to capture anti-lanreotide antibodies present in patient samples, followed by detection using an HRP-conjugated probe and TMB-based colorimetric development. The resulting signal intensity is proportional to the concentration of anti-lanreotide antibodies in the sample, enabling quantitative determination through interpolation from a standard curve. With intra-assay and inter-assay coefficients of variation (CVs) consistently below 30%, the kit delivers reliable and reproducible quantitative immunogenicity data suitable for clinical research applications. The kit is validated for use with human serum and plasma matrices and is classified as a research use only (RUO) product, not intended for diagnostic procedures.
The Anti-Lanreotide ELISA Kit provides a validated, quantitative analytical platform for the detection of anti-lanreotide antibodies in human serum and plasma, addressing the critical immunogenicity monitoring requirements associated with long-term somatostatin analog therapy for acromegaly and gastroenteropancreatic neuroendocrine tumors. By enabling systematic screening and quantitative measurement of anti-drug antibody responses, this assay kit supports the integration of immunogenicity data into pharmacokinetic-pharmacodynamic analysis, clinical trial safety evaluation, and post-marketing surveillance programs. As the therapeutic landscape for somatostatin analogs continues to expand with the development of novel receptor subtype-selective compounds and long-acting formulations, standardized immunogenicity assessment tools such as the Anti-Lanreotide ELISA Kit will remain essential for ensuring the safe and effective clinical application of lanreotide and its emerging biosimilar counterparts. Together with complementary research resources targeting the somatostatin receptor, growth hormone, and IGF-1 pathways, this validated assay system provides a comprehensive analytical infrastructure for researchers advancing the understanding and clinical development of somatostatin analog therapeutics.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25286 | Anti-Lanreotide ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
Loading ......
